International Journal of Head and Neck Surgery

Register      Login

VOLUME 11 , ISSUE 2 ( April-June, 2020 ) > List of Articles


Carcinoma Ex-pleomorphic Adenoma: A Case for Cure

Champion Venkateshalu Srinivas

Keywords : CAXP, Malignancy, Prognosis, Salivary gland

Citation Information : Srinivas CV. Carcinoma Ex-pleomorphic Adenoma: A Case for Cure. Int J Head Neck Surg 2020; 11 (2):32-35.

DOI: 10.5005/jp-journals-10001-1351

License: CC BY-NC 4.0

Published Online: 01-04-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Carcinoma ex-pleomorphic adenoma (CXPA) is an aggressive salivary gland malignant tumor. Diagnosis is difficult as the residual-mixed tumor is small and poorly understood due to the presence of various subtypes. Adenoma carcinoma and salivary duct carcinoma are two common subtypes. Prognostic factors are tumor size, grade, and clinical and pathological stages.

  1. Gerughty RM, Scofield HH, et al. Malignant mixed tumors of salivary gland origin. Cancer 1969;24:471–486. DOI: 10.1002/1097-0142(196909)24:3<471::AID-CNCR2820240309>3.0.CO;2-0.
  2. Beahrs OH, Woolner LB, et al. Carcinomatous transformation of mixed tumors of the parotid gland. AMA Arch Surg 1957;75:605–614. DOI: 10.1001/archsurg.1957.01280160115015.
  3. Foote FW, Frazell EL. Tumors of the major salivary glands. Cancer 1953;6:1065–1133. DOI: 10.1002/1097-0142(195311)6:6<1065::AID-CNCR2820060602>3.0.CO;2-0.
  4. Lewis JE, McKinney BC, et al. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996;77: 223–230. DOI: 10.1002/(SICI)1097-0142(19960115)77:2<223::AID-CNCR1>3.0.CO;2-N.
  5. Patey DH, Thackray AC, et al. Malignant disease of the parotid. Br J Cancer 1965;19:712–737. DOI: 10.1038/bjc.1965.84.
  6. LiVolsi VA, Perzin KH. Malignant mixed tumors arising in salivary glands. I. Carcinomas arising in benign mixed tumors: a clinicopathologic study. Cancer 1977;39:2209–2230. DOI: 10.1002/1097-0142(197705)39:5<2209::AID-CNCR2820390540> 3.0.CO;2-8.
  7. Ihrler S, Weiler C, et al. Intraductal carcinoma is the precursor of carcinoma ex pleomorphic adenoma and is often associated with dysfunctional p53. Histopathology 2007 Sep;51(3):362–371. DOI: 10.1111/j.1365-2559.2007.02736.x.
  8. Brandwein M, Huvos AG, et al. Noninvasive and minimally invasive carcinoma ex mixed tumor: a clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no?) malignant potential. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Jun;81(6):655–664. DOI: 10.1016/S1079-2104(96)80071-0.
  9. Deguchi H, Hamano H, et al. c-myc, ras p21 and p53 expression in pleomorphic adenoma and its malignant form of the human salivary glands. Acta Pathol Jpn 1993 Jul-Aug;43(7–8):413–422. DOI: 10.1111/j.1440-1827.1993.tb01152.x.
  10. Righi PD, Li YQ, et al. The role of the p53 gene in the malignant transformation of pleomorphic adenomas of the parotid gland. Anticancer Res 1994 Sep-Oct;14(5B):2253–2257.
  11. Ohtaké S, Cheng J, et al. Precancerous foci in pleomorphic adenoma of the salivary gland: recognition of focal carcinoma and atypical tumor cells by P53 immunohistochemistry. J Oral Pathol Med 2002 Nov;31(10):590–597. DOI: 10.1034/j.1600-0714.2002.00040.x.
  12. Freitas LL, Araujo VC, et al. Biomarker analysis in carcinoma ex pleomorphic adenoma at an early phase of carcinomatous transformation. Int J Surg Pathol 2005 Oct;13(4):337–342. DOI: 10.1177/106689690501300405.
  13. Lewis JE, Olsen KD, et al. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 2001 Jun;32(6):596–604. DOI: 10.1053/hupa.2001.25000.
  14. Rosa JC, Fonseca I, et al. Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Histopathology 1996 Mar;28(3):247–252. DOI: 10.1046/j.1365-2559.1996.d01-424.x.
  15. Patel RS, Hughes CW, et al. Cyclin A expression and its diagnostic value in pleomorphic adenoma and carcinoma expleomorphic adenoma of the parotid gland. Histopathology 2007 Jul;51(1):21–25. DOI: 10.1111/j.1365-2559.2007.02729.x.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.